Medtronic (MDT) said Friday it has received CE Mark approval in Europe for its Affera Sphere-360 catheter and has completed the first cases in the US Horizon 360 IDE pivotal trial.
Sphere-360 is an all-in-one mapping and single-shot pulsed field ablation catheter meant to treat paroxysmal atrial fibrillation, the company said.
Medtronic also said the CE mark approval was supported by European study results that showed "excellent efficacy, safety, and durability."
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments